Abstracts tagged "proteomics"

Abstract Number: 0502 • ACR Convergence 2020
Integration of Clinical and Protein Markers Through Machine Learning to Distinguish Patients with Psoriasis Arthritis from Those with Psoriasis Without Psoriatic Arthritis
Sara Rahmati¹, Fatima Abji¹, Proton Rahman² and Vinod Chandran³, ¹University Health Network, Toronto, ON, Canada, ²Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic Arthritis (PsA) is a progressive inflammatory arthritis that occurs in about 24% of psoriasis patients. Early diagnosis of PsA is associated with better…
Abstract Number: 0513 • ACR Convergence 2020
Mass Spectrometry Identifies Novel Biomarkers in Giant Cell Arteritis, Useful in Patients on Interleukin-6 Receptor Blockade
Sebastian Unizony¹, Robert Morris², Johannes Kreuzer², Wilhelm Haas² and John H. Stone¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA
Background/Purpose: We aimed to identify biomarkers of disease activity in giant cell arteritis (GCA) patients treated with prednisone monotherapy and with prednisone in combination with…
Abstract Number: 0752 • ACR Convergence 2020
Serum Proteomics Implicates Neutrophil Degranulation in Rheumatoid Arthritis Disease Activity
Liam O'Neil¹, Vidyanand Anaparti¹, Dana Wiens¹, Irene Smolik¹, Xiaobo Meng¹ and Hani El-Gabalawy¹, ¹University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Though targeted therapeutics have improved outcomes in Rheumatoid Arthritis (RA) treatment, the understanding of the underlying biological mechanisms that mediate inflammatory arthritis in RA…
Abstract Number: 0763 • ACR Convergence 2020
Plasmatic Proteome in Individuals with Arthralgia at Risk of Developing Rheumatoid Arthritis
Klára Prajzlerová¹, Nora Petrovská¹, Monika Gregová¹, Jiří Baloun², Petra Hánová², Karel Pavelka¹, Jiří Vencovský¹, Ladislav Šenolt¹ and Mária Filková¹, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic
Background/Purpose: The presence of antibodies against citrullinated proteins (ACPA) significantly increases the risk of developing rheumatoid arthritis (RA). EULAR characterised individuals with arthralgia suspicious for…
Abstract Number: 0936 • ACR Convergence 2020
Urine Proteomics and Single Cell Transcriptomics Identify IL-16 as a Biomarker for Lupus Nephritis
Andrea Fava¹, Jill Buyon², Chandra Mohan³, Ting Zhang³, H. Michael Belmont⁴, Peter Izmirly⁵, Robert Clancy⁶, Jose Monroy-Trujillo⁷, Celine Berthier⁸, Anne Davidson⁹, Nir Hacohen¹⁰, David Wofsy¹¹, Deepak Rao¹², Soumya Raychaudhuri¹³, The Accelerating Medicines Partnership in SLE Network¹⁴, William Apruzzese¹⁵ and Michelle Petri¹⁶, ¹Johns Hopkins University, Baltimore, MD, ²Department of Medicine, NYU School of Medicine, New York, NY, ³UT Houston, Houston, ⁴New York University, New York, NY, ⁵Department of Medicine, New York University School of Medicine, New York, NY, ⁶NYU School of Medicine, New York, ⁷Johns Hopkins University, Baltimore, ⁸University of Michigan, Ann Arbor, ⁹Northwell Health, New York, ¹⁰Broad Institute, Boston, ¹¹University of California San Francisco, San Francisco, CA, ¹²Brigham and Women's Hospital, Boston, MA, ¹³Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁴Multiple Institutions, Multiple Cities, ¹⁵., Boston, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Treatment of lupus nephritis relies on renal histopathological features. However, renal biopsies do not capture patient-specific active biological pathways. Urine proteomic biomarkers could revolutionize…
Abstract Number: 0953 • ACR Convergence 2020
Long-term Xanthine Oxidase Inhibitor Treat to Target Urate Lowering Therapy Coordinately Re-wires the Mononuclear Leukocyte Mitochondrial and Inflammatory Proteome in Gout
Jacob Wozniak¹, Ru Bryan², David Gonzalez³ and Robert Terkeltaub⁴, ¹UC San Diego, San Diego, CA, ²UCSD, San Diego, CA, ³UC San Diego, San Diego, CO, ⁴VA Medical Center/UC San Diego, San Diego, CA
Background/Purpose: In gout, long-term xanthine oxidase inhibitor treat to target urate lowering therapy (XOIT2T) markedly reduces flares and synovitis, despite delayed resolution of tissue crystal…
Abstract Number: 1359 • ACR Convergence 2020
Targeted Serum Proteomic Analysis Following Upadacitinib Treatment in Ankylosing Spondylitis Shows Robust Suppression of Innate and Adaptive Immune Pathways with Tissue Repair Modulation
Thierry Sornasse¹, In-Ho Song², Timothy Radstake³ and Dennis McGonagle⁴, ¹AbbVie Immunology Clinical Development, Redwood City, ²AbbVie Inc., North Chicago, IL, ³AbbVie Immunology Clinical Development, North Chicago, ⁴The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients with active ankylosing spondylitis (AS) with an inadequate response (IR) to…
Abstract Number: 36 • 2019 ACR/ARP Annual Meeting
Discovery, Verification and Validation of Rheumatoid Arthritis Activity Monitoring Biomarkers
Lucía González-Rodríguez¹, Valentina Calamia ¹, Rocío Paz-González ¹, Patricia Fernández-Puente ¹, Cristina Ruiz-Romero ¹, Antonio Julià ², Antonio Fernández-Nebro ³, Jesús Tornero ⁴, Sara Marsal ⁵ and Francisco J. Blanco ⁶, ¹Proteomics Group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña,15006 A Coruña-Spain, A Coruña, Galicia, Spain, ²Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Catalonia, Spain, ³UGC Reumatología, Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Spain., Málaga, Andalucia, Spain, ⁴Hospital Universitario Guadalajara, Guadalajara, Spain., Guadalajara, Castilla-La Mancha, Spain, ⁵Vall d’Hebron Hospital, Barcelona, Catalonia, Spain, ⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a long-lasting inflammatory autoimmune disorder that ultimately leads to the destruction of joint architecture. The activity of this disease is…
Abstract Number: 1722 • 2019 ACR/ARP Annual Meeting
Mixed Cryoglobulin Immune Complex Proteomics: Analysis by Mass Spectroscopy
Peter Gorevic¹, Frank Eng ², Andrea Branch ³, Ahmed Elshamy ⁴, Erin Doyle ² and Thomas Schiano ², ¹Mount Sinai Hospital, New York, ²Mount Sinai Medical Center, New York, ³Mount Sinai Medical School, New York, ⁴California Northstate University, Sacramento
Background/Purpose: BACKGROUND. Mixed Cryoglobulins (MCs) are cold precipitable Rheumatoid Factors (RFs) that provide a biomarker for immune complex formation, particularly associated with chronic Hepatitis C…
Abstract Number: 1944 • 2019 ACR/ARP Annual Meeting
Two Biomarkers with Predictive Capacity to Diagnosis Pre-Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative
María Camacho-Encina¹, Vanesa Balboa-Barreiro ², Rocío Paz-González ³, Valentina Calamia ³, Lucía Lourido ⁴, Patricia Fernández-Puente ³, Cristina Ruiz-Romero ⁵ and Francisco J. Blanco ⁶, ¹Proteomics Group-ProteoRed/ISCIII, Grupo de Investigación de Reumatología (GIR), INIBIC – Hospital Universitario de A Coruña, A Coruña, Spain., A Coruña, Spain, ²Grupo de Investigación de Reumatología (GIR), INIBIC-Hospital Universitario de A Coruña, A Coruña, Spain, A Coruña, Galicia, Spain, ³Proteomics Group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña,15006 A Coruña-Spain, A Coruña, Galicia, Spain, ⁴Proteomics Group-ProteoRed/ISCIII, RIER, Grupo de Investigación de Reumatología (GIR), INIBIC – Hospital Universitario de A Coruña, A Coruña, Spain., A Coruña, Spain, ⁵Proteomics Group-ProteoRed/ISCIII, CIBER-BBN, Grupo de Investigación de Reumatología (GIR), INIBIC – Hospital Universitario de A Coruña, A Coruña, Spain., A Coruña, Spain, ⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain
Background/Purpose: Osteoarthritis (OA) is the most prevalent rheumatic disorder of the middle-age population. The lack of sensitive diagnostics methods led to an identification of the…
Abstract Number: 2405 • 2019 ACR/ARP Annual Meeting
Protein Biomarkers Predicting the Response to IFX+MTX+LEF Treatment in Patients with Rheumatoid Arthritis
Jian Chen ¹, Meng-shi Tang ², Li-chang Xu ³, Shu Li ², Yan Ge ², Jing Tian ², Xi Xie ², Jin-wei Chen ², Jin-feng Du ² and Fen Li¹, ¹Department of Rheumatology and Immunology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China, Changsha, ²Department of Rheumatology and Immunology, The Second Xiangya Hospital, Central South University, Changsha, ³International Department of YALI High School, Changsha
Background/Purpose: Patients with rheumatoid arthritis (RA) usually receive triple therapy with methotrexate (MTX), leflunomide (LEF) and infliximab (IFX), but nearly one-third of them do not…
Abstract Number: 2742 • 2019 ACR/ARP Annual Meeting
Toward a Liquid Biopsy for Lupus Nephritis: Urine Proteomic Analysis of SLE Identifies Inflammatory and Macrophage Signatures
Andrea Fava¹, Yuji Zhang ², Jill Buyon ³, H. Michael Belmont ⁴, Peter Izmirly ⁵, Chandra Mohan ⁶, Ting Zhang ⁷, The Accelerating Medicines Partnership ⁸ and Michelle Petri ⁹, ¹Johns Hopkins University, Baltimore, ²University of Maryland, Baltimore, ³NYU School of Medicine, New York, ⁴New York University School of Medicine, Ney York, ⁵New York University School of Medicine, New York, ⁶University of Houston, Houston, ⁷Biomedical Engineering, University of Houston, Houston, TX, ⁸Multiple Organizations, USA, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) complicates up to 60% of patients with systemic lupus erythematosus (SLE) and carries a high morbidity and mortality. The definitive diagnosis…
Abstract Number: 1972 • 2018 ACR/ARHP Annual Meeting
Resolving the Synovial Fluid Proteome and Peptidome for Disease-Specific Mediators of Inflammatory Arthritis
Shalini Mahendran¹, Eleftherios Diamandis² and Vinod Chandran³, ¹Laboratory Medicine and Pathobiology, University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ²Pathology and Laboratory Medicine, University of Toronto, Mount Sinai Hospital, University Health Network, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Idiopathic inflammatory arthritis (IA) is a T-cell driven chronic condition characterized an imbalance in cell proliferation and apoptosis leading to significant synovial hyperplasia and…
Abstract Number: 2899 • 2018 ACR/ARHP Annual Meeting
Sustained Drug-Free Remission in Early RA Following Methotrexate-Based Strategy: Role of the JAK-STAT Pathway
Xavier M Teitsma¹, Johannes W. G. Jacobs², Arno N Concepcion³, Attila Pethö-Schramm⁴, Michelle EA Borm⁵, Jacob van Laar¹, Johannes W. J. Bijlsma⁶ and Floris PJG Lafeber¹, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ²Rheumatolgy & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴F. Hoffmann-La Roche, Basel, Switzerland, ⁵Roche Nederland BV, Woerden, Netherlands, ⁶Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: We previously identified several co-expressed genes associated with achieving sustained drug-free remission (sDFR) following a methotrexate (MTX)-based strategy in early rheumatoid arthritis (RA).1 The…
Abstract Number: 899 • 2018 ACR/ARHP Annual Meeting
Changes in the Systemic Sclerosis Molecular Signatures after Myeloablation Followed By Autologous Hematopoietic Stem Cell Transplantation and Their Clinical Correlates
Shervin Assassi¹, Xuan Wang², Jun Ying³, Lynette Keyes-Elstein⁴, Ellen Goldmuntz⁵, Jacob Turner⁶, Wenjin Zheng⁷, Guocai Chen⁷, Maria Virginia Pascual⁸, John Varga⁹, Monique Hinchcliff¹⁰, Chiara Bellocchi¹¹, Peter McSweeney¹², Daniel E. Furst¹³, Richard Nash¹², Leslie Crofford¹⁴, Beverly Welch¹⁵, Ashley Pinckney¹⁶, Maureen D. Mayes¹ and Keith Sullivan¹⁷, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Baylor Scott & White Health, Dallas, TX, ³Department of Internal Medicine - Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁴Rho, Inc, Chapel Hill, NC, ⁵NIAID, National Institutes of Health, Bethesda, MD, ⁶Stephen F Austin University, Nacogdoches, TX, ⁷University of Texas Health Science Center at Houston, Houston, TX, ⁸Drukier Institute for Children's Health, Weill Cornell Medicine, New York, NY, ⁹Northwestern University, Chicago, IL, ¹⁰Rheumatology, Northwestern University, Chicago, IL, ¹¹Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ¹²Colorado Blood Cancer Institute, Denver, CO, ¹³University of California Los Angeles, Los Angeles, CA, ¹⁴Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ¹⁵National Institutes of Health, Bethesda, MD, ¹⁶Rho Federal Systems, Inc., Chapel Hill, NC, ¹⁷Duke University Medical Center, Durham, NC
Background/Purpose: Myeloablation followed by autologous hematopoietic stem cell transplantation (HSCT) led to improved clinical outcomes compared to 12 monthly infusions of cyclophosphamide (CYC) in patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].